Your browser doesn't support javascript.
E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies
Wei Bu Wang; Yu Liang; Yu Qin Jin; Jing Zhang; Ji Guo Su; Qi Ming Li.
  • Wei Bu Wang; Yanshan University
  • Yu Liang; National Vaccine and Serum Institute
  • Yu Qin Jin; National Vaccine and Serum Institute
  • Jing Zhang; National Vaccine and Serum Institute
  • Ji Guo Su; Yanshan University
  • Qi Ming Li; National Vaccine and Serum Institute
Preprint in English | bioRxiv | ID: ppbiorxiv-431566
Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article
ABSTRACT
The pandemic of the COVID-19 disease caused by SARS-CoV-2 has led to more than 100 million infections and over 2 million deaths worldwide. The progress in the developments of effective vaccines and neutralizing antibody therapeutics brings hopes to eliminate the threat of COVID-19. However, SARS-CoV-2 continues to mutate, and several new variants have been emerged. Among the various naturally-occurring mutations, the E484K mutation shared by both the 501Y.V2 and 501Y.V3 variants attracted serious concerns, which may potentially enhance the receptor binding affinity and reduce the immune response. In the present study, the molecular mechanism behind the impacts of E484K mutation on the binding affinity of the receptor-binding domain (RBD) with the receptor human angiotensin-converting enzyme 2 (hACE2) was investigated by using the molecular dynamics (MD) simulations combined with the molecular mechanics-generalized Born surface area (MMGBSA) method. Our results indicate that the E484K mutation results in more favorable electrostatic interactions compensating the burial of the charged and polar groups upon the binding of RBD with hACE2, which significantly improves the RBD-hACE2 binding affinity. Besides that, the E484K mutation also causes the conformational rearrangements of the loop region containing the mutant residue, which leads to more tight binding interface of RBD with hACE2 and formation of some new hydrogen bonds. The more tight binding interface and the new hydrogen bonds formation also contribute to the improved binding affinity of RBD to the receptor hACE2. In addition, six neutralizing antibodies and nanobodies complexed with RBD were selected to explore the effects of E484K mutation on the recognition of these antibodies to RBD. The simulation results show that the E484K mutation significantly reduces the binding affinities to RBD for most of the studied neutralizing antibodies, and the decrease in the binding affinities is mainly owing to the unfavorable electrostatic interactions caused by the mutation. Our studies revealed that the E484K mutation may improve the binding affinity between RBD and the receptor hACE2, implying more transmissibility of the E484K-containing variants, and weaken the binding affinities between RBD and the studied neutralizing antibodies, indicating reduced effectiveness of these antibodies. Our results provide valuable information for the effective vaccine development and antibody drugs design.
Full text: Available Collection: Preprints Database: bioRxiv Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines / Variants Language: English Year: 2021 Document Type: Preprint

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Collection: Preprints Database: bioRxiv Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines / Variants Language: English Year: 2021 Document Type: Preprint